Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 21 | 2026 | 1925 | 2.720 |
Why?
|
| Vancomycin | 8 | 2025 | 95 | 1.840 |
Why?
|
| Osteomyelitis | 2 | 2025 | 146 | 1.530 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2025 | 72 | 1.190 |
Why?
|
| Outpatients | 5 | 2024 | 447 | 1.090 |
Why?
|
| Adenosine Monophosphate | 2 | 2025 | 85 | 1.020 |
Why?
|
| Alanine | 2 | 2025 | 169 | 1.000 |
Why?
|
| Tetracyclines | 5 | 2026 | 16 | 0.950 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2025 | 9 | 0.940 |
Why?
|
| Enterococcus faecium | 2 | 2025 | 22 | 0.930 |
Why?
|
| Teicoplanin | 2 | 2021 | 15 | 0.850 |
Why?
|
| Arthritis, Infectious | 1 | 2025 | 76 | 0.810 |
Why?
|
| Ritonavir | 2 | 2023 | 75 | 0.780 |
Why?
|
| Antiviral Agents | 4 | 2025 | 769 | 0.760 |
Why?
|
| Organ Transplantation | 2 | 2024 | 253 | 0.720 |
Why?
|
| beta-Lactamases | 1 | 2022 | 53 | 0.690 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 11 | 0.670 |
Why?
|
| Aspergillosis | 1 | 2021 | 24 | 0.670 |
Why?
|
| Candidiasis | 1 | 2021 | 64 | 0.660 |
Why?
|
| Cephalosporins | 4 | 2026 | 45 | 0.640 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2026 | 365 | 0.630 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 251 | 0.630 |
Why?
|
| Staphylococcal Infections | 2 | 2021 | 393 | 0.580 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 874 | 0.550 |
Why?
|
| Blood Coagulation Factors | 1 | 2018 | 71 | 0.520 |
Why?
|
| Hospitalization | 5 | 2025 | 2461 | 0.500 |
Why?
|
| Retrospective Studies | 19 | 2026 | 17330 | 0.420 |
Why?
|
| Sepsis | 1 | 2020 | 664 | 0.400 |
Why?
|
| Hemorrhage | 1 | 2018 | 822 | 0.370 |
Why?
|
| Kidney | 2 | 2023 | 1497 | 0.370 |
Why?
|
| Critical Illness | 1 | 2019 | 900 | 0.360 |
Why?
|
| Treatment Outcome | 9 | 2026 | 11794 | 0.340 |
Why?
|
| Humans | 36 | 2026 | 145783 | 0.330 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 261 | 0.330 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 962 | 0.320 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 674 | 0.300 |
Why?
|
| Aged | 14 | 2026 | 26217 | 0.280 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2026 | 77 | 0.260 |
Why?
|
| Immunocompromised Host | 2 | 2025 | 202 | 0.250 |
Why?
|
| Adult | 15 | 2026 | 40881 | 0.250 |
Why?
|
| Azabicyclo Compounds | 1 | 2026 | 7 | 0.240 |
Why?
|
| Ceftazidime | 1 | 2026 | 7 | 0.240 |
Why?
|
| Middle Aged | 13 | 2026 | 36309 | 0.230 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2026 | 49 | 0.230 |
Why?
|
| Escherichia coli Infections | 1 | 2026 | 125 | 0.220 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 134 | 0.220 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2026 | 397 | 0.210 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2024 | 8 | 0.210 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2024 | 22 | 0.210 |
Why?
|
| Recurrence | 2 | 2025 | 1139 | 0.210 |
Why?
|
| Health Care Rationing | 1 | 2024 | 56 | 0.210 |
Why?
|
| Cystitis | 1 | 2024 | 24 | 0.200 |
Why?
|
| Aminoglycosides | 1 | 2024 | 30 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2026 | 247 | 0.200 |
Why?
|
| beta-Lactams | 2 | 2023 | 32 | 0.200 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 46 | 0.200 |
Why?
|
| Immune Reconstitution | 1 | 2023 | 10 | 0.200 |
Why?
|
| Endocarditis | 1 | 2024 | 40 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 2 | 2023 | 340 | 0.190 |
Why?
|
| Lactams | 1 | 2023 | 28 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 1043 | 0.190 |
Why?
|
| Acinetobacter Infections | 1 | 2022 | 15 | 0.190 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 26 | 0.180 |
Why?
|
| Proline | 1 | 2023 | 82 | 0.180 |
Why?
|
| Leucine | 1 | 2023 | 116 | 0.180 |
Why?
|
| Male | 16 | 2026 | 73011 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 3 | 2024 | 1505 | 0.180 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 103 | 0.180 |
Why?
|
| Pseudomonas Infections | 1 | 2024 | 231 | 0.180 |
Why?
|
| Mycobacterium abscessus | 1 | 2023 | 110 | 0.170 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 47 | 0.170 |
Why?
|
| Nitriles | 1 | 2023 | 211 | 0.170 |
Why?
|
| Escherichia coli | 1 | 2026 | 835 | 0.170 |
Why?
|
| Creatinine | 2 | 2023 | 515 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 172 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 206 | 0.170 |
Why?
|
| Clostridium Infections | 1 | 2022 | 74 | 0.170 |
Why?
|
| Daptomycin | 1 | 2021 | 18 | 0.170 |
Why?
|
| Female | 15 | 2026 | 79045 | 0.170 |
Why?
|
| Plasmids | 1 | 2022 | 373 | 0.160 |
Why?
|
| Antifungal Agents | 1 | 2021 | 152 | 0.160 |
Why?
|
| Colorado | 3 | 2025 | 4556 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2021 | 165 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2023 | 339 | 0.140 |
Why?
|
| Machine Learning | 1 | 2024 | 587 | 0.140 |
Why?
|
| Burns | 1 | 2023 | 374 | 0.140 |
Why?
|
| Vitamin K | 1 | 2018 | 46 | 0.140 |
Why?
|
| Hemostatics | 1 | 2018 | 64 | 0.130 |
Why?
|
| Isoantibodies | 1 | 2017 | 57 | 0.130 |
Why?
|
| Bacteremia | 3 | 2026 | 222 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 699 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 668 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2017 | 240 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 2933 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2022 | 968 | 0.110 |
Why?
|
| Graft Survival | 1 | 2017 | 519 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2017 | 521 | 0.100 |
Why?
|
| Logistic Models | 1 | 2019 | 2139 | 0.100 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 1163 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2019 | 924 | 0.090 |
Why?
|
| Transplant Recipients | 2 | 2024 | 182 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 2383 | 0.090 |
Why?
|
| Risk Factors | 3 | 2024 | 10919 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2017 | 680 | 0.080 |
Why?
|
| Standard of Care | 2 | 2022 | 81 | 0.080 |
Why?
|
| Quality of Life | 1 | 2021 | 3211 | 0.070 |
Why?
|
| Cefotaxime | 1 | 2026 | 3 | 0.060 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2026 | 22 | 0.060 |
Why?
|
| Ceftriaxone | 1 | 2026 | 21 | 0.060 |
Why?
|
| Cefazolin | 1 | 2026 | 22 | 0.060 |
Why?
|
| Enterococcus faecalis | 1 | 2025 | 29 | 0.060 |
Why?
|
| Utah | 1 | 2025 | 80 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2026 | 396 | 0.050 |
Why?
|
| Subcutaneous Tissue | 1 | 2024 | 26 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2024 | 85 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
|
| Viremia | 1 | 2024 | 160 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2023 | 80 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2026 | 867 | 0.050 |
Why?
|
| Piperacillin | 1 | 2023 | 7 | 0.050 |
Why?
|
| Acetates | 1 | 2023 | 78 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 27 | 0.050 |
Why?
|
| Minocycline | 1 | 2022 | 23 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 168 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2025 | 1330 | 0.040 |
Why?
|
| Quinazolines | 1 | 2023 | 266 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2023 | 189 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2022 | 360 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2024 | 318 | 0.040 |
Why?
|
| Health Policy | 1 | 2024 | 400 | 0.040 |
Why?
|
| Gentamicins | 1 | 2021 | 50 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1038 | 0.040 |
Why?
|
| Rifampin | 1 | 2021 | 79 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 354 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 765 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 189 | 0.040 |
Why?
|
| Skin | 1 | 2024 | 754 | 0.040 |
Why?
|
| United States | 2 | 2026 | 16126 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 2934 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 1202 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 971 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1547 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 1165 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 8347 | 0.020 |
Why?
|
| Adolescent | 2 | 2024 | 22577 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1491 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2024 | 8078 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 3118 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 2410 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 14254 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 4302 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 6465 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 10091 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 11868 | 0.010 |
Why?
|
| Child | 1 | 2017 | 22740 | 0.010 |
Why?
|